Neuphoria Therapeutics (NEUP) Return on Sales (2024 - 2025)

Neuphoria Therapeutics (NEUP) posted quarterly Return on Sales of 1.69% for Q2 2025, up 22393.48% quarter-over-quarter from 0.01% in Q1 2025.

Neuphoria Therapeutics (NEUP) Return on Sales (2024 - 2025) Analysis & Trends

Neuphoria Therapeutics (NEUP) has reported Return on Sales for 2 consecutive years, with 1.69% the latest figure, recorded in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	139.70 Bn	131.85 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	86.74 Bn	78.75 Bn	3.93 Bn	0.00%
3	Argenx Se	65.36 Bn	60.18 Bn	1.37 Bn	0.00%
4	Moderna	59.15 Bn	54.01 Bn	52.00 Mn	-0.05%
5	BeOne Medicines	42.12 Bn	37.02 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.88 Bn	28.57 Bn	992.69 Mn	0.00%
7	BioNTech SE	28.14 Bn	9.75 Bn	668.28 Mn	0.00%
8	Insmed	27.59 Bn	26.43 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.31 Bn	26.48 Bn	-	0.00%
10	Neuphoria Therapeutics	21.64 Mn	2.20 Mn	-	-

Download Data